Navigation Links
Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
Date:12/2/2008

HillmanCancerCenter Joins Trial with James Pingpank, MD, FACS, as Principal Investigator

NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Hillman Cancer Center of the University of Pittsburgh Medical Center (UPMC), has joined Delcath's Phase III clinical trial testing its Percutaneous Hepatic Perfusion (PHP) System against inoperable metastatic melanoma in the liver. James Pingpank, MD, FACS, Associate Professor Surgery in the Department of Surgical Oncology, will serve as the Principal Investigator at UPMC, while maintaining his role as Extramural Adjunct Principal Investigator for the entire multi-center trial. This pivotal multi-center study for the isolated, high dose delivery of the anti-cancer agent melphalan is led by the National Cancer Institute (NCI). UPMC is the eleventh center to join this trial, and is a leading liver transplant center and a pioneer in cutting-edge regional liver therapy techniques. This trial is now enrolling at the following centers:

  • National Cancer Institute in Bethesda, Maryland
  • University of Pittsburgh, Pennsylvania
  • John Wayne Cancer Institute in Santa Monica, California
  • Moffitt Cancer Center in Tampa, Florida
  • Swedish Medical Center in Englewood, Colorado
  • Providence Cancer Center in Portland, Oregon
  • University of Maryland Medical Center in Baltimore, Maryland
  • Albany Medical Center in Albany, New York
  • St. Luke's Cancer Center in Bethlehem, Pennsylvania
  • Morristown Memorial Hospital in Morristown, New Jersey
  • University of Texas Medical Branch in Galveston, Texas

(Photo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Commenting on joining this Phase III study, Dr. Pingpank stated, "This is an extraordinary time for the PHP method, and we continue to gather the statistical data regarding its utility in this otherwise untreatable cancer. I have worked with this technology for many years, and am pleased to lead the trial at Pittsburgh as we complete enrollment in this study, and explore other viable options for its use, including colorectal metastasis, neuroendocrine metastasis and primary liver cancer."

Richard L. Taney, President and CEO of Delcath commented, "Dr. Pingpank has continued his commitment to and involvement with this System since joining UPMC, and we are delighted that he will be leading the push to further accelerate the momentum that we have been experiencing. We look forward to continue working with Jim, and to work with the other world renowned clinicians at UPMC, who have demonstrated international leadership in the field of regional cancer therapies."

About the University of PittsburghMedicalCenter

UPMC is an integrated global health enterprise headquartered in Pittsburgh, Pennsylvania, and one of the leading nonprofit health systems in the United States. As western Pennsylvania's largest employer, with 50,000 employees and $7 billion in revenue, UPMC is transforming the economy of the region into one based on medicine, research, and technology. By integrating 20 hospitals, 400 doctors' offices and outpatient sites, long-term care facilities, and a major health insurance services division, UPMC has advanced the quality and efficiency of health care and developed internationally renowned programs in transplantation, cancer, neurosurgery, psychiatry, orthopaedics, and sports medicine, among others. UPMC is commercializing its medical and technological expertise by nurturing new companies, developing strategic business relationships with some of the world's leading multinational corporations, and expanding into international markets, including Italy, Ireland, the United Kingdom, and Qatar. For more information about UPMC, visit our website at www.upmc.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
2. Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman
3. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
4. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
5. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
6. Medical Simulation Corporation Announces Partnership With University of South Florida
7. Winning University of Melbourne Ph.D. research boosts the search for sensitive sensors
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis
10. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
11. Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 01, 2016 , ... ... through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were on ... than 100 clinical trial leaders from over 40 sponsor, CRO and site organizations to ...
(Date:12/2/2016)... Washington, DC (PRWEB) , ... ... ... Technologies Consortiumâ„¢ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to ... is seeking companies interested in supplying a vendor-supported, portable online UHPLC, with ...
(Date:12/2/2016)... Dec. 1, 2016   SurePure, Inc. (OTCQB: ... that the Company has concluded an agreement with Tamarack ... a 90-day period to acquire units of the Company,s ... USD 3.7 million.  Concurrently with the ... under which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
Breaking Biology News(10 mins):